Not medical advice. Talk to your provider before using any peptide. Full disclaimer
TRT (Testosterone Replacement Therapy)
Also known as: Test C, Test Cyp, Depo-Testosterone
The TRAVERSE trial followed 5,246 men for a median of 33 months and settled one of medicine's longest running arguments: testosterone replacement does not increase heart attacks or strokes (HR 0.96, 95% CI 0.78 to 1.17). Testosterone cypionate is an FDA approved injectable that restores serum testosterone in men with diagnosed hypogonadism, defined as total T below 300 ng/dL on two separate morning draws. The FDA removed its cardiovascular black box warning in March 2025. Roughly 208,000 members of r/Testosterone track protocols, labs, and dose adjustments in real time, making TRT one of the most community documented therapies in medicine.
What Is TRT (Testosterone Replacement Therapy)?
Testosterone Replacement Therapy (TRT) is the medical administration of exogenous testosterone cypionate or enanthate to men whose bodies don't produce enough on their own. The TRAVERSE trial (n=5,246)[1] confirmed cardiovascular safety, and the FDA removed its black box warning in March 2025. The diagnostic bar is straightforward: total testosterone below 300 ng/dL on two separate morning blood draws, confirmed by symptoms like fatigue, reduced libido, erectile dysfunction, muscle loss, and depressed mood.
Injectable testosterone cypionate comes as a 200 mg/mL oil based solution in 10 mL multi dose vials. Unlike peptides, there's no reconstitution step. You draw directly from the vial with an 18 to 20 gauge needle, switch to a 23 to 25 gauge injection needle, and inject intramuscularly or subcutaneously.
The community side of TRT is enormous. Over 208,000 members on r/Testosterone share bloodwork, protocols, and real world outcomes. Community consensus and clinical evidence have converged on twice weekly split dosing (every 3.5 days), subcutaneous injection preference, and avoiding routine aromatase inhibitor use. A 2018 meta-analysis of 4 placebo-controlled trials (1,779 men) found small gains in libido, erectile function and sexual satisfaction, no effect on energy or mood, and a higher erythrocytosis risk (relative risk 8.14, 95% CI 1.87 to 35.40; Ponce et al.)[2]. Secondary endpoints from TRAVERSE (pulmonary embolism, atrial fibrillation) were raised versus placebo, so risk benefit still requires clinical judgment.
How TRT (Testosterone Replacement Therapy) Works
Testosterone cypionate is an esterified prodrug. After intramuscular injection into the gluteal or deltoid muscle, the oil depot releases testosterone cypionate slowly into surrounding tissue. Esterases in the blood cleave the cypionate ester, freeing active testosterone.
Free testosterone binds androgen receptors in the cytoplasm of target cells throughout the body. Skeletal muscle, bone, brain, adipose tissue, skin, and reproductive organs all carry these receptors. The testosterone androgen receptor complex moves into the nucleus and is a transcription factor. It binds androgen response elements on DNA and upregulates protein synthesis, particularly myosin heavy chain and local IGF-1 production in muscle.
In bone, androgen receptor activation stimulates osteoblast proliferation and inhibits osteoclast activity. Two enzymatic conversions matter clinically. 5 alpha reductase converts testosterone to dihydrotestosterone, a more potent androgen responsible for prostate growth and hair follicle miniaturization. Aromatase converts testosterone to estradiol, which is necessary for bone health and libido but problematic in excess.
Rising testosterone and estradiol exert negative feedback on GnRH pulsatility in the hypothalamus. That suppresses LH and FSH from the pituitary. This feedback loop is why exogenous testosterone causes testicular atrophy and impaired spermatogenesis within weeks of starting therapy.
TRT (Testosterone Replacement Therapy) Benefits
- TRT benefits center on restoring what hypogonadism takes away, with clinical trial data and community reports pointing to the same outcomes.
- Serum testosterone restored to the 400 to 700 ng/dL physiological range on standard doses of 75 to 200 mg per week (Depo-Testosterone FDA label).
- Lean mass increases and fat mass drops, per a meta-analysis of 59 randomized trials of testosterone (Corona et al. 2016)[3].
- Libido, erectile quality, and sexual function improve, with return of morning erections being the first signal most community members report around weeks 3 to 6.
- Bone mineral density increases over 12 to 24 months, reducing fracture risk in men with osteopenia secondary to hypogonadism.
- Testosterone deficiency anemia corrects on therapy. The TRAVERSE sub study confirmed hemoglobin improvements in anemic hypogonadal men [1].
- Mood, motivation, and cognitive clarity improve. Community members on r/Testosterone frequently describe the shift as "feeling like myself again" after months or years of low T symptoms.
TRT (Testosterone Replacement Therapy): Science vs Community Consensus
FDA-approved exogenous testosterone restores physiological serum levels in diagnosed hypogonadal men.
Read the evidence (key study, limitations)
TRAVERSE trial (n=5,246, NEJM 2023) established non-inferiority for MACE (HR 0.96, 95% CI 0.78–1.17). Strong efficacy evidence for libido, body composition, bone density, and anemia correction. FDA removed cardiovascular black box warning March 2025. Secondary endpoints (PE, AF) remain elevated vs. placebo: risk-benefit still requires clinical judgment.
Lincoff AM et al. Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE). NEJM 2023; PMID 37326322
TRAVERSE enrolled men with pre-existing or high-risk CV disease: generalizability to low-risk younger men uncertain. Secondary endpoints (pulmonary embolism, atrial fibrillation) were elevated vs. placebo. Optimal dosing target range not definitively established in RCTs. Long-term prostate safety data beyond 5 years remains limited.
Described as "life-changing" for symptomatic low T. Strong consensus on split-dose twice-weekly injections, SubQ preference, and avoiding routine AI use.
Read the reports (what users report 5, common issues 6)
Main frustrations are hematocrit management, estrogen dialing, and injection logistics.
- Energy and vitality restoration: commonly described as "feeling like myself again"
- Libido and sexual function recovery, including return of morning erections
- Mood, motivation, and mental clarity improvement
- Lean mass gain and visceral fat reduction over 3–6 months
- Correction of testosterone-deficiency fatigue and anemia
- Hematocrit elevation requiring therapeutic phlebotomy or dose reduction
- Estrogen management difficulty: AI overuse crashing E2 is common mistake
- Injection site pain, lumps, bruising (especially SubQ with cold oil)
- Finding a knowledgeable prescriber: GP frustration a common theme on r/Testosterone
- Testicular atrophy and fertility concerns without HCG/gonadorelin
- Lab timing confusion (trough vs. mid-cycle) leading to misjudged dose adjustments
Science and community are strongly aligned on TRT efficacy and core protocols. Community split-dosing practice (E3.5D) and SubQ preference are now supported by clinical evidence. Main community divergence: some members self-administer at upper clinical or supraphysiologic doses without formal hypogonadism diagnosis. Community has largely adopted the clinical consensus against routine AI use.
TRT (Testosterone Replacement Therapy) Dosage Guide
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 75 mgNo source supports a lower starting dose, so this tier repeats the moderate dose. | 2x/week |
| Moderate | 75 mg | 2x/week |
| Aggressive | 100 mg | 2x/week |
TRT isn't a peptide. It's exogenous testosterone. But it shows up on this platform because it's commonly stacked with peptides like gonadorelin or HCG for fertility preservation.
Testosterone cypionate comes as a ready to use oil solution at 200 mg/mL. No reconstitution math here; you're drawing volume directly. For the common split dose of 75 mg twice weekly, draw 0.375 mL (37 to 38 units). At 100 mg per injection, you need 0.5 mL (50 units).
The thing most beginners miss: warm the vial in your hands for 60 seconds before drawing. Cold oil is thick and painful going in. Splitting your weekly dose into two injections every 3.5 days produces more stable blood levels and reduces estrogen spikes; the community figured this out before the clinical literature caught up.
Get baseline bloodwork before your first injection. Total testosterone, free testosterone, estradiol (sensitive assay), SHBG, CBC with hematocrit, PSA, and a lipid panel. Non negotiable.
Cycling
No scheduled off period.
TRT is a continuous, lifelong therapy, not cycled. Stopping abruptly causes a crash in testosterone levels that can take months to recover from (if natural production recovers at all). If discontinuation is desired, work with an endocrinologist on a PCT protocol using enclomiphene, gonadorelin, or HCG to restart the HPG axis.
TRT is a continuous, lifelong therapy, not cycled. The HPG axis is suppressed by exogenous testosterone within weeks (LH and FSH fall to near-zero). Stopping abruptly causes a testosterone crash that can take months to recover from; in men with primary hypogonadism, natural production may never return. If discontinuation is desired, a medically supervised post-TRT protocol using enclomiphene, gonadorelin, or HCG is required to attempt HPG axis restart.
- If stopping: profound fatigue, low libido, and depression within days to weeks
- Endogenous LH/FSH remain suppressed for weeks to months post-cessation even after exogenous T clears
- Testicular size may partially recover with HCG/gonadorelin but often not fully after extended TRT
- Natural testosterone production recovery is highly variable and cannot be guaranteed in primary hypogonadism
Or use the universal Peptide Calculator for any peptide.
TRT (Testosterone Replacement Therapy) Protocols by Goal
Expected: Total T restored to 400–700 ng/dL trough; libido improvement by weeks 3–6; body composition changes by months 3–6
Monitor: Trough total T, free T, E2 (sensitive assay), hematocrit, PSA, lipids, BP at 6 weeks; then 3 months; then every 6–12 months
How to Use TRT (Testosterone Replacement Therapy)
- 1Step 1
Wash hands thoroughly and prepare supplies: testosterone vial, alcohol swabs, 18 to 20 gauge drawing needle, 23 to 25 gauge 1 to 1.5 inch injection needle (or 27 to 29 gauge 0.5 inch insulin syringe for SubQ), sharps container.
- 2Warm the testosterone vial in your hands for 60 seconds
Oil based testosterone flows more easily when warm, and cold oil causes more post injection pain.
- 3Swab the vial stopper with alcohol
Draw air into the syringe equal to your dose volume, inject air into the vial, then invert and draw your dose. For 75 mg from a 200 mg/mL vial, draw to 37 to 38 units (0.375 mL). For 100 mg, draw to the 50 unit mark (0.5 mL).
- 4Switch from the drawing needle to your injection needle
Tap out air bubbles and push plunger until a small drop appears at the needle tip.
- 5Clean the injection site with alcohol
Preferred sites: ventrogluteal (safest, best absorption), vastus lateralis (outer thigh), or deltoid for IM. For SubQ, inject into abdominal or thigh fat.
- 6Step 6
For IM: insert the needle at 90 degrees in one smooth motion. Aspirate briefly. Inject slowly over 15 to 20 seconds. For SubQ: pinch skin, insert at 45 to 90 degrees, inject slowly.
- 7Step 7
Withdraw the needle and apply gentle pressure with a cotton ball. Do not rub. Rotate injection sites each time to prevent scar tissue buildup.
- 8Step 8
Store the vial at room temperature (20 to 25 degrees Celsius). Do not refrigerate or freeze oil based testosterone.
Alternative Routes
Same mg dose; some patients require 10–20% higher weekly dose SubQ vs. IM to achieve equivalent trough levels due to slower peak absorption from SubQ depot
27–29g 0.5-inch insulin syringe into abdominal fat, thigh, or deltoid fat. Lower peak/trough variation, less E2 spike, less hematocrit elevation vs. IM. Strong patient preference over IM in switch studies. FDA label specifies IM only for Depo-Testosterone, but Xyosted (SubQ testosterone enanthate auto-injector) is FDA-approved SubQ. PMID 34698352 supports clinical equivalence.
1.62% gel: 20.25–81 mg/day applied daily; achieves lower and more variable serum levels than injectable; ~30% effective dose relative to injectable in practice
Transference risk to women and children via skin contact: significant concern in households with partners or children. No injection required. Daily application is adherence burden. More expensive per dose than injectable generic. Preferred by patients who cannot or will not inject.
75–450 mg implanted SubQ every 3–6 months; dose fixed at insertion: no adjustment possible after placement
Consistent serum levels without weekly injections. Irreversible once implanted: side effects cannot be managed by dose reduction until pellets absorb. Minor surgical insertion procedure required. Pellet extrusion rate ~5–8%.
750 mg IM on day 1, again at 4 weeks, then every 10 weeks; extremely infrequent dosing but extreme peaks/troughs
Risk of serious pulmonary oil microembolism (POME) requires 30-minute post-injection observation at a certified healthcare facility: cannot self-inject. Available only through REMS program.
TRT (Testosterone Replacement Therapy) Stacking Protocols
Works With
Maintains testicular volume and intratesticular testosterone for fertility preservation during TRT. Acts as an LH analog: stimulates Leydig cells to prevent complete testicular atrophy.
250 IU SubQ every other day (EOD), concurrent with TRT
Modern HCG alternative for LH/FSH stimulation and HPG axis maintenance. More physiologic pulsatile GnRH stimulation vs. sustained LH analog.
50–100 mcg SubQ 2–3×/week concurrent with TRT
Central melanocortin agonist for sexual function; addresses residual ED or libido issues not fully resolved by TRT alone.
1.75 mg SubQ 45–60 min before sexual activity, PRN
Hypothalamic GnRH stimulator; experimental adjunct for HPG axis support. Occasionally stacked by biohackers. No established clinical TRT protocol.
Research use only; no established TRT co-protocol
Avoid
Routine AI use crashes estradiol: joint pain, low libido, and fatigue from E2 deficiency are identical to high-E2 symptoms, creating a mismanagement cycle. Only use if E2 confirmed elevated by LC-MS/MS AND symptomatic.
Opioids independently suppress the HPG axis (opioid-induced hypogonadism): TRT dose requirements increase and optimization is confounded. Co-administration without monitoring is high-risk.
Testosterone may potentiate anticoagulant effect and increase INR/bleeding risk. Close INR monitoring and potential dose adjustment required if co-prescribed.
Stacking exogenous AAS with TRT provides no additional therapeutic benefit and compounds hematocrit, cardiovascular, and hepatic risks well beyond clinical range.
Do not combineEstimated Cost
Pricing updated 2026-04-09
TRT (Testosterone Replacement Therapy) Side Effects
Hematocrit elevation is the lab abnormality that demands the most attention. Testosterone stimulates erythropoiesis, pushing red blood cell production higher. When hematocrit exceeds 54%, blood viscosity rises and so does clot risk. Therapeutic phlebotomy or dose reduction becomes necessary at that threshold. This isn't a theoretical concern; it's the most common reason clinicians adjust TRT protocols.
Testosterone aromatizes to estradiol via the aromatase enzyme. Raised estradiol causes water retention, gynecomastia, and mood instability. The community learned a painful lesson about managing this: routine aromatase inhibitor use crashed estradiol in thousands of men, producing joint pain, low libido, and fatigue identical to high estrogen symptoms. The current clinical consensus reserves anastrozole only for men with LC-MS/MS confirmed raised estradiol AND symptomatic complaints.
Acne and oily skin affect roughly 15 to 25% of users. Shoulders and back are the typical sites. DHT mediated hair loss accelerates in men genetically predisposed to male pattern baldness; finasteride blocks this conversion but also limits some androgenic benefits.
TRT suppresses the hypothalamic pituitary gonadal axis. Testes shrink. Sperm production drops to near zero in most men within months. Anyone wanting future fertility needs concurrent HCG or gonadorelin to maintain intratesticular testosterone and spermatogenesis.
The TRAVERSE trial flagged higher rates of pulmonary embolism and atrial fibrillation versus placebo as secondary endpoints. These findings warrant monitoring, not dismissal.
PSA may increase modestly on therapy. Men with untreated prostate cancer or a PSA above 4 ng/mL without urological clearance should not start TRT. Sleep apnea can worsen in susceptible individuals. Mood irritability and increased aggression show up occasionally at supraphysiologic doses but are uncommon at clinical replacement levels.
Contraindications are clear: active or history of hormone sensitive prostate cancer, male breast cancer, polycythemia above 54%, severe untreated sleep apnea, uncontrolled heart failure (NYHA Class III to IV), pregnancy or exposure to pregnant women (Category X), and desire for near term fertility without gonadotropin support.
Common Issues & Solutions
Hematocrit rising above 50%: reduce weekly dose by 10–20% or extend injection interval; therapeutic phlebotomy (donate blood) if >54%; rule out undiagnosed sleep apnea as contributing cause
Estradiol crash symptoms (joint pain, low libido, fatigue) while on AI: stop anastrozole: E2-crash symptoms are identical to high-E2 symptoms; use sensitive LC-MS/MS E2 assay to confirm level before initiating or continuing AI
Mid-week testosterone crash (fatigue, mood drop 4–5 days after weekly injection): switch from once-weekly to twice-weekly E3.5D split dosing; SubQ absorption curve is smoother than IM for some men
Injection site lumps or subcutaneous nodules: warm oil to room temperature before drawing; inject slowly over 15–20 seconds; rotate sites every injection; consider switching to SubQ insulin syringe technique for smaller, less painful depots
Testosterone levels declining after months of stability: verify consistent lab draw timing (always trough or always mid-cycle: not mixed); check injection technique for site/depth changes; assess body weight change affecting SHBG; suspect compounded testosterone lot-to-lot variability
Ask AI about this page
Ask AI for a second opinion on TRT (Testosterone Replacement Therapy) dosing and side effects
Contraindications
- Prostate cancer (current or history of hormone-sensitive prostate cancer)
- Male breast cancer
- Polycythemia (hematocrit above 54%): withhold until resolved
- Severe untreated sleep apnea
- Uncontrolled heart failure (NYHA Class III-IV)
- Desire for near-term fertility without concurrent gonadotropin support
- Pregnancy or potential exposure to pregnant women (teratogenic: Category X)
- Known hypersensitivity to testosterone or any formulation component
- Unevaluated prostate nodule or PSA above 4 ng/mL without urological clearance
Drug Interactions
- Anticoagulants (warfarin, heparin): testosterone may increase INR and bleeding risk; monitor closely and adjust dose
- Insulin and oral hypoglycemics: testosterone can improve insulin sensitivity, potentially causing hypoglycemia; dose adjustment may be needed
- Corticosteroids: concurrent use increases edema risk due to sodium and fluid retention
- Aromatase inhibitors (anastrozole, exemestane): commonly co-prescribed but over-suppression of estradiol causes joint pain, low libido, and bone loss
- CYP3A4 inhibitors (ketoconazole, ritonavir): may increase testosterone levels by slowing hepatic metabolism
- 5-alpha reductase inhibitors (finasteride, dutasteride): block conversion to DHT, may reduce androgenic side effects but also limit some benefits
- Warfarin / oral anticoagulants
- Testosterone may potentiate anticoagulant effect and increase INR/bleeding risk. Close INR monitoring and potential dose adjustment required if co-prescribed.
Product Quality
Pharmaceutical-grade testosterone cypionate is FDA-approved, widely available at US retail pharmacies, and subject to full pharmaceutical QC. Risk is low for prescription-dispensed product. Compounded testosterone (503A/503B pharmacies) carries moderate quality risk due to less stringent batch-to-batch testing. Unregulated or research-grade sources carry high risk.
- Use only FDA-approved pharmaceutical-grade testosterone cypionate (generic or Depo-Testosterone) from licensed US pharmacies
- For compounded testosterone, the quality markers are PCAB accreditation (503A) and FDA registration (503B)
- Inspect vials: oil should be clear, not cloudy or particulate; discard any abnormal-appearing vial
- Compounded testosterone has documented batch-to-batch potency variability: if levels drop unexpectedly on stable dose, suspect lot change and consider switching to pharmaceutical-grade
- Never use unregulated online sources: adulteration with other AAS or incorrect concentration is a documented risk
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Total testosterone (trough) | Baseline, week 6, month 3, month 6, then every 6–12 months | 400–700 ng/dL (trough, immediately before next injection) |
| Free testosterone | Baseline, week 6, when symptoms do not match total T result | 70–150 pg/mL (equilibrium dialysis method preferred) |
| Estradiol sensitive (LC-MS/MS assay) | Baseline, week 6, month 3, whenever E2-related symptoms suspected | 20–40 pg/mL (sensitive assay; do not use standard immunoassay) |
| SHBG | Baseline, then annually or when free T is rechecked | Not listed |
| Hematocrit / CBC | Baseline, week 6, month 3, then every 3–6 months | <54% (hold therapy and investigate if exceeded) |
| PSA | Baseline, month 3, month 6, then annually | Rise <1.4 ng/mL above baseline within 12 months; absolute <4 ng/mL without urological clearance |
| Lipid panel | Baseline, month 6, then annually | Not listed |
| Blood pressure | Baseline, then at each clinical encounter | Not listed |
| Metabolic panel (LFTs, BMP) | Baseline, annually | Not listed |
Confirm dosing achieves target therapeutic range
High SHBG can make normal total T functionally hypogonadal; free T is the bioactive fraction
Aromatization of testosterone to E2; elevated E2 causes water retention and gynecomastia; crashed E2 (from AI overuse) causes joint pain and low libido
Determines bioavailable fraction; high SHBG requires higher total T target to achieve adequate free T
Testosterone stimulates erythropoiesis; hematocrit >54% increases blood viscosity and VTE risk
TRT does not cause prostate cancer but can accelerate pre-existing hormone-sensitive disease; track velocity
Testosterone may modestly reduce HDL; baseline and ongoing CV risk assessment
FDA now requires product-specific BP monitoring language (post-TRAVERSE postmarket ABPM studies); TRT can elevate BP in susceptible individuals
Baseline organ function; LFTs relevant for AI co-administration; renal function for risk stratification
TRT (Testosterone Replacement Therapy) Before and After
Testosterone levels begin rising within 24-48 hours of the first injection. Most men don't notice subjective changes yet. Slight improvements in energy and mood may appear toward week 2-3. Serum trough levels aren't stable until about 4-5 half-lives (~5-6 weeks).
Libido and sexual function often improve noticeably. Morning erections return in previously hypogonadal men. Energy and motivation begin to pick up. First follow-up labs should be drawn at 6 weeks (trough level, before next injection).
Body composition changes start: early increases in lean mass and reductions in visceral fat. Mood stabilizes. Hematocrit may begin climbing. Estradiol should be checked. Dose adjustments are commonly made at this stage based on bloodwork.
Full effects on muscle mass, strength, and fat loss become apparent. Bone mineral density improvements are measurable. Red blood cell count and hematocrit reach new equilibrium: monitor closely. Lipid panel changes may appear (HDL may decrease slightly).
Maximum therapeutic benefits are reached by 9-12 months. Body composition and libido reach steady state. Ongoing monitoring every 6-12 months: CBC, metabolic panel, testosterone, estradiol, PSA, and lipids.
What to Expect
Weeks 1 to 3: Testosterone levels start rising within 24 to 48 hours of the first injection, but steady state trough won't arrive for another 5 to 6 weeks. Most men report minimal subjective change during this window. Some notice a slight uptick in energy around week 2 or 3. Patience matters here; your body is catching up to the new supply.
Weeks 3 to 6: This is when most men notice something concrete. Morning erections return. Libido picks up in a way that feels different from placebo. Energy and motivation start building. First trough labs should be drawn at week 6, right before your next injection. Don't adjust dose before you have data.
Weeks 6 to 12: Body composition changes become visible. Early lean mass gains and reductions in visceral fat start showing. Hematocrit may begin climbing. Estradiol should be checked. This is the window where most dose adjustments happen based on that week 6 bloodwork. The AI debate among community members peaks during this stretch.
Months 3 to 6: Full therapeutic effects take hold. Lean mass increases are measurable by DXA. Visceral fat drops. Mood stabilizes into what long term users call "the new normal." Some men need their first therapeutic phlebotomy around this time. PSA and lipid panels should be rechecked.
Months 6 to 12 and beyond: Maximum benefits reached by 9 to 12 months. Body composition and libido reach steady state. Bone density improvements continue accumulating for 2 or more years. Monitoring shifts to every 6 to 12 months: CBC, metabolic panel, testosterone, estradiol, PSA, and lipids.
Detailed Timeline: Science vs Community
Testosterone levels rise within 24–48 hours of first injection. Steady-state trough not reached for ~5–6 half-lives (~5–6 weeks). No measurable body composition change possible yet.
Most report minimal change. Some notice slightly improved energy by week 2–3. Occasional temporary acne flare. Libido change minimal or non-existent at this stage.
Serum T approaching steady state. Libido and morning erections begin responding. First trough labs should be drawn at week 6.
Return of morning erections frequently reported as first concrete signal of effect. Libido noticeably improved. Energy picking up. Labs may confirm T in range but not yet fully optimized.
Hematocrit reaching new equilibrium. Estradiol levels stabilizing. Early lean mass and fat loss becoming measurable. Dose adjustments commonly made at this stage based on week-6 trough labs.
First dose adjustments. AI debates peak during this window. Body composition changes becoming visible. Some report needing AI; majority feel best without it.
Lean mass increases measurable by DXA. Visceral fat reduction apparent. Bone mineral density improvements begin. Lipid panel may show modest HDL reduction. RBC count at new equilibrium.
"Full effect" commonly described at 3–4 months. Strength gains, fat loss, mood stability all reported. Some require first therapeutic phlebotomy. PSA and lipid check advised.
Body composition and libido at maximum therapeutic benefit. Bone density improvements continue for 2+ years. Ongoing monitoring every 6–12 months.
"The new normal." Most well-dialed in on dose, schedule, and monitoring. Long-term users describe it as permanent lifestyle management rather than a treatment course.
Pharmacokinetics
Source: FDA label: terminal half-life ~8 days (192 hours) for testosterone cypionate IM; Bi et al. 2018 population PK study reported median post-hoc half-life of 4.05 days for total testosterone appearance
Pharmacokinetics: Active Dose Over Time
t½ = ~8 days (testosterone cypionate IM)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Is TRT (Testosterone Replacement Therapy) Legal?
Testosterone cypionate (Depo-Testosterone) is FDA approved for the treatment of hypogonadism in men. It is a Schedule III controlled substance under the Controlled Substances Act, requiring a valid prescription from a licensed provider. Generic testosterone cypionate is available at nearly all US retail pharmacies. Compounded testosterone from 503A or 503B pharmacies is also widely available through TRT clinics and telehealth platforms.
Testosterone is prohibited by WADA at all times, both in and out of competition. Athletes subject to anti doping testing should not use TRT without a Therapeutic Use Exemption, which is rarely granted at the professional level.
No pending regulatory changes affect injectable testosterone cypionate availability. The March 2025 removal of the cardiovascular black box warning simplified prescribing but added product specific blood pressure monitoring language based on TRAVERSE postmarket data.
This content is for informational purposes only and does not constitute medical advice. TRT requires medical supervision, ongoing lab monitoring, and a valid prescription. Consult a qualified healthcare provider before starting testosterone therapy.
Who Should Consider TRT (Testosterone Replacement Therapy)
- Men with diagnosed hypogonadism (total testosterone consistently below 300 ng/dL)
- Men with age-related testosterone decline and symptomatic low T
- Post-anabolic steroid users with suppressed HPTA seeking medically supervised restoration
- Men with secondary hypogonadism from pituitary dysfunction or chronic opioid use
- Transgender men undergoing masculinizing hormone therapy
Related Peptides
What Changed for TRT (Testosterone Replacement Therapy)
- Dosing
Corrected Oct 9, 2026: the 80 mg weekly TRT tier had no source; the label gives 50 to 400 mg every 2 to 4 weeks, per the Depo-Testosterone label.
Before: Beginner 80 mg weekly After: No source supports this dose; removed. The beginner tier now repeats the 75 mg twice-weekly moderate dose, with a note.
Source: Depo-Testosterone (testosterone cypionate) prescribing information (openFDA label record, SPL version 26, effective Aug 21, 2026) (opens in a new tab) · Saved copy
Peptide Schedule Research TeamReviewed Apr 7, 20265 Citations
References
- [1]Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE Trial): Lincoff et al., NEJM 2023 (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]The efficacy and adverse events of testosterone replacement therapy in hypogonadal men: A systematic review and meta-analysis of randomized, placebo-controlled trials: Ponce et al., J Clin Endocrinol Metab 2018 (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]Testosterone supplementation and body composition: results from a meta-analysis study: Corona et al., Eur J Endocrinol 2016 (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is TRT (Testosterone Replacement Therapy)?
Hot. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: Tens of thousands of. Community mentions on Reddit: Tens of thousands of threads. Open r/trt (size varies; historically quarantined) (opens in a new tab).
2,496 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
Very high search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.